
Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer

Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day

Abata Therapeutics to Present at Upcoming September Investor Conferences

Abata Therapeutics to Participate in the Guggenheim I&I Spotlight Series – Treg-Based Therapies

Abata Therapeutics to Present at Upcoming Investor Conferences

Abata Therapeutics Appoints Sandy Lazzari as Chief People Officer
